Daily Roundup

NXT.ASX NAB.ASX YAL.ASX 4DX.ASX LDX.ASX

NEXTDC Announces Transformational Increase in Contracted Utilisation and A$2.2 Billion Capital Plan

NEXTDC Limited (ASX: NXT) has delivered a remarkable update, reporting a transformational 60% increase in its pro forma contracted utilisation to 667MW. This record 250MW expansion at the company's S4 facility has also driven an 83% surge in NEXTDC's pro forma Forward Order Book to 544MW as of March 31, 2026.

Customers are clearly flocking to NEXTDC, recognizing the company's ability to quickly, reliably, and at scale deliver the critical AI infrastructure they require. To support this accelerated demand, NEXTDC plans to invest approximately A$1.5 billion in the rapid development of S4 through fiscal 2027.

To fund this growth, NEXTDC is undertaking a A$1.5 billion equity raise via a fully underwritten entitlement offer. The company is also increasing its Hybrid Securities Offer by A$700 million, demonstrating strong investor confidence. Additionally, NEXTDC is exploring further capital initiatives, including A$1.5 billion in senior debt and potential joint venture partnerships.

The impressive forward order book is expected to generate over A$1 billion in EBITDA, more than quadrupling NEXTDC's fiscal 2026 guidance. Looking ahead, the company forecasts capex of around A$5 billion for fiscal 2027 to align with its record pipeline.

NEXTDC's bold moves cement its position as the leading provider of mission-critical AI infrastructure in the region. Investors can look forward to the company's continued growth and innovation in the years to come.

NAB Strengthens Balance Sheet, Announces 1H26 Earnings Impacts

National Australia Bank (ASX: NAB) has taken proactive steps to bolster its balance sheet and resilience amid market volatility. The bank has increased its forward-looking collective provisions by A$300 million and applied a 1.5% discount to its 1H26 dividend reinvestment plan, which it has partially underwritten to raise up to A$1.8 billion.

Additionally, NAB has made changes to its software capitalization policy, resulting in a A$1.3 billion accelerated amortization charge in 1H26. This move is expected to lead to higher operating expenses in the second half of the fiscal year, though the bank reaffirms its guidance for cash operating expense growth to be less than 4.6% for the full year.

Despite these one-time impacts, NAB expects to report a pro forma Group CET1 ratio above 12% at the end of March 2026, including the benefits of the dividend reinvestment plan actions.

Yancoal Reports Solid 1Q 2026 Results

Yancoal Australia (ASX: YAL) has delivered a strong start to the year, reporting 15.0 million tonnes of run-of-mine coal production (100% basis) and 9.0 million tonnes of attributable saleable coal production in the first quarter of 2026.

The company's average realized coal price was A$146 per tonne, with a 3% lower realized thermal coal price offset by a 5% higher realized metallurgical coal price compared to the previous quarter. Yancoal's cash operating costs are expected to be towards the top end of the A$90-98 per tonne guidance range for the year, reflecting the impact of higher diesel prices.

Looking ahead, Yancoal's 2026 attributable saleable production guidance remains unchanged at 36.5-40.5 million tonnes, and the company's capital expenditure guidance is A$750-900 million. The recent acquisition of an 80% stake in the Kestrel Coal Mine for US$1.85 billion further strengthens Yancoal's portfolio and growth potential.

4DMedical Secures GSK Contract, Gains UK Clearance, and Joins ASX 200

4DMedical Limited (ASX: 4DX), a global leader in respiratory imaging technology, has announced a series of significant milestones. The company has secured a contract with pharmaceutical giant GlaxoSmithKline (GSK) to provide its proprietary quantitative lung imaging analytics, further validating the demand for 4DMedical's advanced cardiopulmonary imaging platform.

Additionally, 4DMedical's CT:VQ solution has received UKCA certification for clinical use in the United Kingdom, expanding the company's European footprint. This regulatory clearance, combined with the existing CE Mark, positions 4DMedical to engage directly with leading European and UK clinicians and contribute to the global clinical evidence base.

Reflecting the company's significant progress over the past year, including FDA clearance of CT:VQ and deployment at six leading U.S. academic medical centers, 4DMedical has been included in the S&P/ASX 200 Index.

Lumos Diagnostics Reports Strong Q3 FY26 Results

Lumos Diagnostics Holdings Ltd (ASX: LDX) has delivered a robust performance in the third quarter of fiscal year 2026, reporting a 37% increase in revenue to US$4.8 million. This growth was driven by strong sales of the company's FebriDx® diagnostic product, which recently received 510(k) clearance and a CLIA waiver from the U.S. FDA, expanding its addressable market to approximately 80 million patients per annum.

Lumos also received significant milestone payments totaling US$5.5 million from PHASE Scientific and the Biomedical Advanced Research and Development Authority (BARDA), further strengthening its financial position. The company completed a successful A$20 million placement and launched a Share Purchase Plan offer, bolstering its balance sheet.

Looking ahead, Lumos expects to receive an additional US$3.4 million in non-dilutive milestone payments from Hologic related to the ongoing development of its fFN diagnostic product.